The Genetics and Epigenetics of Fatigue

Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Montebello, Norway.
PM&R (Impact Factor: 1.66). 05/2010; 2(5):456-65. DOI: 10.1016/j.pmrj.2010.04.003
Source: PubMed

ABSTRACT Fatigue is a common symptom and includes both physical and mental components. It can be associated with a variety of different syndromes and diseases, but in many cases is not associated with other comorbid conditions. Most humans have experienced acute fatigue in relation to different stressors. Acute fatigue typically decreases as the effect of the triggering factor is reduced and a normal homeostatic balance is restored. Fatigue that persists for 6 months or more is termed chronic fatigue. Chronic fatigue (CF) in combination with a minimum of 4 of 8 symptoms and the absence of diseases that could explain these symptoms, constitute the case definition for chronic fatigue syndrome. In spite of its prevalence, the biology of fatigue is relatively poorly understood and biological markers have not yet been identified. This literature search was performed in PubMed to identify research on the genetics and epigenetics of fatigue. Publications were included if fatigue was a major topic and the topic was combined with genetic and/or epigenetic measurements in adult humans. A total of 40 publications were identified. Although altered functioning in the hypothalamic-pituitary-adrenal axis, the serotonergic system, and associations with infectious agents have been identified, the search for genetic or epigenetic markers of fatigue, either in the context of CF or chronic fatigue syndrome (CFS) has been relatively unproductive or, in the case of epigenetics, nonexistent. Although several studies, both hypothesis-testing and hypothesis-generating, have been performed to search for biomarkers, they have mostly been underpowered, restricted by the heterogeneity of the phenotype, or limited by an unsystematic study design. To be able to confirm the hypothesis that risk for, or levels of, fatigue are influenced by the genetic or epigenetic background of an individual, studies need to be based on larger sample sizes with a more clearly defined phenotype. Studies need to focus not only on the influence of a single aspect such as single nucleotide polymorphisms (SNPs) or differential gene expression on disease risk or state, but also on the systems biology behind the disease in combination with information on environmental influences and validation of findings in functional studies.

  • [Show abstract] [Hide abstract]
    ABSTRACT: As the median age of the global population rises, the incidence of cancer is also set to increase, leading to a growing elderly population with cancer. Despite this trend, older patients have traditionally been under-represented in the majority of oncology trials. This is largely due to their heterogeneous nature and extended medical histories that have the potential to hinder treatment. Indeed, it is widely recommended that patients' suitability for a given treatment should not be based on age alone, but rather by an assessment of physiological age on an individual basis. As evidence grows that existing therapies, such as chemotherapy, can be suitable for older patients, the management of these patients has become of increasing importance to oncologists. In particular, the management of haematological toxicities and their effects may be key to achieving optimal clinical outcomes among patients undergoing chemotherapy. Using two of the most common haematological toxicities, anaemia and neutropenia, as examples, we explore current therapies for elderly patients with cancer, and discuss the future management of this growing patient population.
    Journal of Geriatric Oncology 07/2012; 3(3):246–255. DOI:10.1016/j.jgo.2012.04.004 · 1.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Research on pediatric Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is reviewed in this article. Many recent articles in this area highlight the existence of key differences between the adult and pediatric forms of the illness. This review article provides an overview of pediatric ME/CFS, including epidemiology, diagnostic criteria, treatment, and prognosis. Challenges to the field are identified with the hope that in the future pediatric cases of ME/CFS can be more accurately diagnosed and successfully managed.
    01/2012; 3(4):257-270.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die Ätiopathologie somatoformer Störungen ist nur vor dem Hintergrund eines biopsychozialen Modells integriert darstellbar. Hierbei müssen kulturelle wie historische Einflüsse ebenso berücksichtigt werden wie die jeweils aktuell vorherrschende Schwerpunktsetzung in Forschung und Praxis. Vor diesem Hintergrund ist die Betonung neurobiologischer Befunde auch als das nicht zufällige Ringen von Betroffenen wie deren Behandlern um Legitimität zu interpretieren. Die Datenlage zu Einflussfaktoren auf Entstehung und Aufrechterhaltung somatoformen Geschehens ist ebenso divers wie weitgehend unspezifisch und weist damit auf ein noch abzuarbeitendes Forschungsprogramm hin.
    Der Nervenarzt 09/2012; 83(9). DOI:10.1007/s00115-011-3444-y · 0.86 Impact Factor


Available from
Jun 1, 2014